No Data
No Data
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $3
Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Natera (NTRA)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Express News | Mersana Therapeutics Inc : Guggenheim Cuts Target Price to $5 From $7
Mersana Therapeutics Selloff on Data Overdone, Says BTIG
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
EUGENE啊梁 : Garbage